As a downstream target of the AKT/mTOR/HIF-1α signaling pathway, Galectin-1 is a possible biomarker for predicting resistance of sorafenib in HCC in vitro and in vivo (Yeh et al., 2015). This evidence concerns the gene AKT1 and hepatocellular carcinoma.